MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.carrev.2025.07.003

Медицинская библиотека · Cardiovascular revascularization medicine : including molecular interventions · 2025

Impact of elevated lipoprotein(a) on epicardial coronary flow conductance and endoluminal atherosclerotic disease distribution.

Renkens Mick P L, Tsai Tsung-Ying, Revaiah Pruthvi C, Kageyama Shigetaka, Reiber Johan H C, de Winter Robbert J, Grundeken Maik, Nurmohamed Nick S, Stroes Erik, Garg Scot, von Birgelen Clemens, Hofma Sjoerd, Alkhalil Mohammad, Rosseel Liesbeth, Sharif Faisal, Smits Pieter C, Baumbach Andreas, Onuma Yoshinobu, Wykrzykowska Joanna J, Serruys Patrick W

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Elevated lipoprotein(a) [Lp(a)] is associated with accelerated progression of coronary plaques, a higher prevalence of thin-cap fibroatheroma, and an increased risk of spontaneous myocardial infarction. However, Lp(a)'s impact on coronary artery disease (CAD) and the resulting coronary flow dynamics have yet to be fully determined.

OBJECTIVE

To evaluate the effects of elevated Lp(a) levels on epicardial coronary flow and endoluminal disease pattern (focal or diffuse).

METHODS

In a propensity-score matched (PSM) cohort from the ongoing PIONEER IV trial (NCT04923191), participants with de novo CAD and elevated Lp(a) (>50 mg/dL or 120 nmol/L) were matched to controls based on traditional CAD risk factors. Epicardial flow velocity was assessed using the Quantitative Flow Ratio (QFR), with the virtual QFR-Pressure Pullback Gradient Index (QFR-PPGi) characterizing the endoluminal disease phenotype. A QFR ≤ 0.80 indicated significant epicardial flow limitation.

RESULTS

Among 672 consecutively enrolled participants with available Lp(a) measurements, elevated levels were observed in 23 % (152/672). Complete risk profiles for traditional CAD risk factors were available for 391 participants with de novo CAD, of whom 75 had elevated Lp(a) levels. After propensity matching, 75 pairs (150 participants) were eligible for analyses. QFR analyses were completed in 392/450 (87 %) vessels. The median difference in baseline QFR between matched vessels was -0.045 (p = 0.005), while the mean difference in QFR-PPGi was -0.028 (p = 0.013). Vessels from participants with elevated Lp(a) demonstrated significantly higher rates of QFR ≤ 0.80 compared to matched controls (31 % vs. 19 %, absolute risk difference 12 %; 95 % CI: 2.7 %-21 %, p = 0.011).

CONCLUSIONS

Elevated plasma levels of Lp(a) were associated with increased epicardial flow limitation and a more diffuse endoluminal disease pattern.

CONDENSED ABSTRACT: In this PIONEER IV sub-study (NCT04923191), we investigated the effect of elevated lipoprotein(a) [Lp(a)] on epicardial coronary flow and endoluminal disease distribution. We analyzed 392 vessels from 75 propensity-matched pairs using Quantitative Flow Ratio (QFR) to assess flow limitation and the virtual QFR-Pressure Pullback Gradient Index (QFR-PPGi) to characterize disease distribution patterns (focal versus diffuse). Vessels exposed to elevated Lp(a) exhibited significantly higher rates of epicardial flow limitation (QFR ≤ 0.80) than controls (31 % vs. 19 %, absolute risk difference 12 %; 95 % CI: 2.7 %-21 %, p = 0.011). The median difference in baseline QFR between matched vessels was -0.045 (p = 0.005), while the mean difference in QFR-PPGi was -0.028 (p = 0.013). These findings demonstrate that elevated Lp(a) levels are associated with both greater epicardial flow limitation and a more diffuse pattern of coronary artery disease.

Для цитирования: Renkens Mick P L, Tsai Tsung-Ying, Revaiah Pruthvi C, Kageyama Shigetaka, Reiber Johan H C, de Winter Robbert J, Grundeken Maik, Nurmohamed Nick S, Stroes Erik, Garg Scot, von Birgelen Clemens, Hofma Sjoerd, Alkhalil Mohammad, Rosseel Liesbeth, Sharif Faisal, Smits Pieter C, Baumbach Andreas, Onuma Yoshinobu, Wykrzykowska Joanna J, Serruys Patrick W. Impact of elevated lipoprotein(a) on epicardial coronary flow conductance and endoluminal atherosclerotic disease distribution.. Cardiovascular revascularization medicine : including molecular interventions. 2025. DOI: 10.1016/j.carrev.2025.07.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.